Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (BRAVE I)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03616912
Recruitment Status : Terminated (Study terminated due to insufficient evidence to support a positive benefit: risk ratio. Safety findings were consistent with previously published OLUMIANT data)
First Posted : August 6, 2018
Last Update Posted : May 13, 2022
Incyte Corporation
Information provided by (Responsible Party):
Eli Lilly and Company

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : November 1, 2021
Actual Study Completion Date : March 9, 2022